Mechanism of ulcerogenic activity of indomethacin and oxyphenbutazone.
D000311:Adrenal Glands / Q000502:physiology; D000315:Adrenalectomy; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002818:Cordotomy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006834:Hydrazines / Q000494:pharmacology; D007099:Imipramine / Q000494:pharmacology; D007213:Indomethacin / Q000037:antagonists & inhibitors; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010113:Oxyphenbutazone / Q000037:antagonists & inhibitors; D010643:Phenoxybenzamine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011247:Pregnancy; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D013276:Stomach Ulcer / Q000139:chemically induced*
D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D010643:Phenoxybenzamine; D001285:Atropine; D008238:Lysergic Acid Diethylamide; D011433:Propranolol; D010113:Oxyphenbutazone; D007099:Imipramine; D007213:Indomethacin; D010646:Phentolamine